Literature DB >> 7657802

Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload.

O Nakagawa1, Y Ogawa, H Itoh, S Suga, Y Komatsu, I Kishimoto, K Nishino, T Yoshimasa, K Nakao.   

Abstract

We previously demonstrated that brain natriuretic peptide (BNP) is a cardiac hormone mainly produced in the ventricle, while the major production site of atrial natriuretic peptide (ANP) is the atrium. To assess the pathophysiological role of BNP in ventricular overload, we have examined the gene expression of BNP, In comparison with that of ANP, in a model of cardiac hypertrophy using cultured neonatal rat ventricular cardiocytes. During cardiocyte hypertrophy evoked by endothelin-1, Phenylephrine, or PMA, the steady state level of BNP mRNA increased as rapidly as the "immediate-early" induction of the c-fos gene expression, and reached a maximal level within 1 h. Actinomycin D, a transcriptional inhibitor, completely diminished the response, while the translational blocked with cycloheximide did not inhibit it. In contrast, ANP mRNA began to increase 3 h after the stimulation, and accumulated during cardiocyte hypertrophy. The BNP secretion from ventricular cardiocytes was also stimulated, more rapidly than the ANP secretion. Furthermore, the turnover of BNP mRNA was significantly faster than that of ANP mRNA, being consistent with the existence of AUUUA motif in the 3'-untranslated region of BNP mRNA. These results demonstrate that the gene expression of BNP is distinctly regulated from that of ANP at transcriptional and posttranscriptional levels, and indicate that the characteristics of the BNP gene expression are suitable for its possible role as an " emergency" cardiac hormone against ventricular overload.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7657802      PMCID: PMC185749          DOI: 10.1172/JCI118162

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  60 in total

1.  Cis-acting sequences that modulate atrial natriuretic factor gene expression.

Authors:  C E Seidman; D W Wong; J A Jarcho; K D Bloch; J G Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

2.  Augmented expression of atrial natriuretic polypeptide gene in ventricles of spontaneously hypertensive rats (SHR) and SHR-stroke prone.

Authors:  H Arai; K Nakao; Y Saito; N Morii; A Sugawara; T Yamada; H Itoh; S Shiono; M Mukoyama; H Ohkubo
Journal:  Circ Res       Date:  1988-05       Impact factor: 17.367

3.  A new natriuretic peptide in porcine brain.

Authors:  T Sudoh; K Kangawa; N Minamino; H Matsuo
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

4.  A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation.

Authors:  G Shaw; R Kamen
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

5.  Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP).

Authors:  K Kangawa; H Matsuo
Journal:  Biochem Biophys Res Commun       Date:  1984-01-13       Impact factor: 3.575

6.  Nucleotide sequence of the gene encoding human atrial natriuretic factor precursor.

Authors:  B D Greenberg; G H Bencen; J J Seilhamer; J A Lewicki; J C Fiddes
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

7.  Atrial natriuretic peptide elevation in congestive heart failure in the human.

Authors:  J C Burnett; P C Kao; D C Hu; D W Heser; D Heublein; J P Granger; T J Opgenorth; G S Reeder
Journal:  Science       Date:  1986-03-07       Impact factor: 47.728

8.  Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function.

Authors:  Y Saito; K Nakao; K Nishimura; A Sugawara; K Okumura; K Obata; R Sonoda; T Ban; H Yasue; H Imura
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

9.  Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.

Authors:  R J Cody; S A Atlas; J H Laragh; S H Kubo; A B Covit; K S Ryman; A Shaknovich; K Pondolfino; M Clark; M J Camargo
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

10.  Neonatal atria and ventricles secrete atrial natriuretic factor via tissue-specific secretory pathways.

Authors:  K D Bloch; J G Seidman; J D Naftilan; J T Fallon; C E Seidman
Journal:  Cell       Date:  1986-12-05       Impact factor: 41.582

View more
  102 in total

1.  Expression of B-type natriuretic peptide in atrial natriuretic peptide gene disrupted mice.

Authors:  M Y Tse; J D Watson; I R Sarda; T G Flynn; S C Pang
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

2.  Remodeling of the peripheral cardiac conduction system in response to pressure overload.

Authors:  Brett S Harris; Catalin F Baicu; Nicole Haghshenas; Harinath Kasiganesan; Dimitri Scholz; Mary S Rackley; Lucile Miquerol; Daniel Gros; Rupak Mukherjee; Terrence X O'Brien
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

3.  Gab family proteins are essential for postnatal maintenance of cardiac function via neuregulin-1/ErbB signaling.

Authors:  Yoshikazu Nakaoka; Keigo Nishida; Masahiro Narimatsu; Atsunori Kamiya; Takashi Minami; Hirofumi Sawa; Katsuya Okawa; Yasushi Fujio; Tatsuya Koyama; Makiko Maeda; Manami Sone; Satoru Yamasaki; Yuji Arai; Gou Young Koh; Tatsuhiko Kodama; Hisao Hirota; Kinya Otsu; Toshio Hirano; Naoki Mochizuki
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

4.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

Authors:  Talita M Marin; Kimberly Keith; Benjamin Davies; David A Conner; Prajna Guha; Demetrios Kalaitzidis; Xue Wu; Jessica Lauriol; Bo Wang; Michael Bauer; Roderick Bronson; Kleber G Franchini; Benjamin G Neel; Maria I Kontaridis
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

Review 5.  Hypertension, hypertrophy, heart failure.

Authors:  M G Nicholls
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 6.  In hypertension, the kidney breaks your heart.

Authors:  Steven D Crowley; Thomas M Coffman
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

Review 7.  Natriuretic peptide-guided therapy: further research required for still-unresolved issues.

Authors:  R De Vecchis; C Esposito; S Cantatrione
Journal:  Herz       Date:  2013-04-17       Impact factor: 1.443

8.  [Essential cardiac biomarkers in myocardial infarction and heart failure].

Authors:  M Mueller; E Giannitsis; H A Katus
Journal:  Herz       Date:  2014-09       Impact factor: 1.443

9.  Normal values of B type natriuretic peptide in infants, children, and adolescents.

Authors:  A Koch; H Singer
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

10.  B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study.

Authors:  Kirsten Bibbins-Domingo; Maria Ansari; Nelson B Schiller; Barry Massie; Mary A Whooley
Journal:  Circulation       Date:  2003-12-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.